Mycoplasma pneumoniae infections continue to account for a significant proportion of disease due to respiratory infections in military trainees (25) . A number of serological methods have been developed for detecting M. pneumoniae antibody, including immunofluorescence (9, 11, 22, 23) , indirect hemagglutination (23) , tetrazolium reduction inhibition (19) , complement fixation (CF) (7, 10) , and the sensitive radioimmunoprecipitation (1) and mycoplasmacidal tests (2) . Until now, only antibodies detected by the tetrazolium reduction inhibition (21) and fluorescent antibody (8) techniques have been associated with protection against illness.
At Camp Lejeune, N.C., where M. pneumoniae infections are prevalent, we had the unusual opportunity of studying the effect of pre-existing M. pneumoniae antibody on the incidence and severity of natural infection, since sera are obtained from all recruits when they enter training. Knowledge about the effect of pre-existing antibody on natural M. pneumoniae infections will be even more impor- tant when killed and live, attenuated M. pneumoniae vaccines are developed. For instance, recipients of some inactivated virus vaccines developed unusually severe illness when they were later infected with wild virus (3, 13) . In this study we present evidence that high levels of pre-existing antilipid and anti-whole organism CF antibodies were associated with resistance to M. pneumoniae infection Isolation of M. pneumoniae. Throat gargle specimens were obtained in veal infusion broth and inoculated into diphasic medium (16) . The diphasic agar consisted of 3.4 g of Difco pleuropneumonia-like organism (PPLO) agar, 60 ml of distilled deionized water, and 0.1 ml of 2% phenol red solution. This mixture was autoclaved at 121 C for 15 min and then allowed to cool to 56 C. A separate solution consisting of 20 ml of gamma globulin-free horse serum (Grand Island Biological), 10 ml of yeast extract (Microbiological Associates), 10 ml of 10% glucose, 3 ml of thallium acetate, 1.0 ml of 0.2% methylene blue, and 1.0 ml of penicillin (100,000 U/ml) was heated to 56 C. The two solutions were combined and dispensed in 1.0-ml volumes into 2-dram (about 2.4 g) vials. Agar butts solidified at room temperature and were stored at 4 C for up to 30 days.
PPLO broth base contained 3.5 g of PPLO broth powder (Difco), 100 ml of distilled deionized water, and 0.17 ml of 2% phenol red, autoclaved at 121 C for 15 min. The diphasic broth contained 60 ml of PPLO broth base, 30 ml of mycoplasma supplement (33% yeast extract, 66% gamma globulin-free horse serum, Difco), 10 ml of 10% glucose, 3 ml of thallium acetate, 1.0 ml of 0.2% methylene blue, and 1.0 ml of penicillin (10,000 U/ml). The diphasic broth was dispensed in 2.0-ml quantities into the vials containing 1 Liu (17) , was grown on glass in medium similar to that described by Chanock et al. (6) . Nine hundred milliliters of solution was prepared in distilled deionized water and contained 5 .0 g of glucose, 7.4 g of PPLO broth powder without crystal violet (CV) (dehydrated, Difco), 4.8 g of Eagle minimal essential medium powder (Grand Island Biological, F-15), 11.9 g of N-2-hydroxyethylpiperazine-N'-2T-ethanesulfonic acid (HEPES, A grade, Calbiochem). The solution was sterilized by membrane (Millipore Corp.) filtration. PPLO medium (1,000 ml) was prepared by the addition of 50 ml of yeast extract, 50 ml of gamma globulin-free horse serum, 1.25 ml of 2% thallium acetate (Fisher), and 500,000 U of penicillin to the solution. The pH of the medium was adjusted to 7.4 with sodium hydroxide.
Strain FH was stored at -60 C in HEPES broth in 1.0-ml volumes. A 0.5-ml amount of strain FH was inoculated into 40 ml of PPLO medium in 16-oz (about 0.47 liter) Povitsky bottles and incubated horizontally at 37 C until the glass contained a 75 to 90% sheet of PPLO colonies and the pH began to decrease. The medium was then decanted, and attached organisms were washed four times with 10 ml of phosphate-buffered saline (pH 7.3). The organisms were scraped from the glass or removed by freezing and thawing, resuspended in 0.5 ml of distilled water, and pooled. Whole organism CF antigen produced titers of 1: 16 to 1:32 against 4 to 8 U of antibody.
Chloroform-extracted M. pneumoniae lipid CF antigen (15) . Organisms were grown on glass as described above, and the lipids were extracted by shaking with a mixture of chloroform, methanol, and 0.10 N potassium chloride (20:10:7.5). The mixture was allowed to stand for 18 h at 4 C in a separatory funnel. The chloroform fraction was withdrawn and the chloroform was evaporated under a hood. Antigen was suspended in a small amount of phosphate-buffered saline.
CF tests. CF tests were carried out by the microtiter method of Sever (20) , by using 2 exact U of complement and 4 to 8 U of antigen.
Seroepidemiological study of antilipid antibodies. Preinfection, acute, and convalescent sera were obtained from 296 trainees either reporting to the dispensary or hospitalized between August 1970 and February 1971 (Tables 1-3) . Fifty-three were controls reporting to the dispensary with non-respiratory complaints. The remaining 243 were 132 trainees reporting to the dispensary with the chief complaint of symptoms of acute respiratory disease, and 111 were trainees hospitalized with a diagnosis of acute respiratory disease or pneumonia. Predominant microbial agents isolated from these trainees by our laboratory or by the laboratory at the Naval Hopsital, Camp Lejeune, N.C., included M. pneumoniae, adenovirus type 7, and beta hemolytic streptococcus (25) . Additional serological studies revealed a small percentage of parainfluenza type 1 and 3 infections (24) . No attempt was made to exclude individuals infected with more than one agent from the study. All 888 individual serum specimens were tested for the presence of M. pneumoniae antibody by the CF test by using chloroform-extracted M. pneumoniae lipids as antigen (Tables 1-3) , as well as using the whole organism preparation as antigen ( Seroepidemiological studies were begun in August 1969, and the seasonal peaks in the proportion of M. pneumoniae isolations paralleled increases in the proportion of seroconversions (fourfold rises in CF titer) to anti-whole organism antibody (Fig. 2) . Note that there was also an increase in the number of patients with M. pneumoniae pneumonia hospitalized during the summer months of the years 1970 and 1971 (Fig. 3) .
Protective effect associated with pre-existing antibody. CF results discussed in this section apply only to sera obtained on arrival at Parris Island, S.C., and, therefore, before M. pneumoniae infection had occurred. The data presented in Tables 1, 3 Table 3 ). However, pre-existing antilipid antibody titers of 1:4 to 1:8 were not associated with protection against pneumonia (P < 0.70, Table 1 ) and accounted for 35% of the patients with pneumonia. In contrast, only 15% of the patients with M. pneumoniae disease without pneumonia had intermediate levels of pre-existing antilipid antibody ( Table 1) . Relationship of severity of irness to antilipid CF antibody rise. Of interest was the observation that sera obtained from pneumonia patients on arrival at the hospital had higher CF antibody titers than acute-phase sera obtained from trainees ill with M. pneumoniae disease but requiring only outpatient care (Table 5) . Additionally, the convalescent antibody titer in the trainees with more severe disease was higher than those with milder illness (P < 0.001). In M. pneumoniae disease, unlike most viral infections, a twofold increase in geometric mean CF antibody titer occurred by the time a patient required hospitalization.
DISCUSSION
This study supports earlier observations of a seasonal factor in both M. pneumoniae isolations and disease (5, 25 Of trainees studied at Camp Lejeune for acute respiratory disease, 24% of those seroconverting between the acute and convalescent serum specimens had pneumonia. The actual proportion of trainees at Camp Lejeune with M. pneumoniae pneumonia was probably higher than 24% because M. pneumoniae antibody was frequently high by the time of hospital admission, and a further fourfold rise in antibody titer was not always detected in trainees with pneumonia from whom the organism was recovered. The rate of pneumonia among the trainees who seroconverted was high when compared with rates reported in previous studies (8, 12) , and the high rate was probably related to the surveillance techniques used. All hospitalized trainees were studied, whereas studies were carried out on only 5 to 10% of trainees reporting to the dispensary for acute respiratory disease. A more accurate estimate of the pneumonia rate is probably that of Chanock and co-workers, who reported that clinically diagnosed pneumonia occurred in only one of 30 trainees experiencing a seroconversion to M. pneumoniae by the fluorescent antibody method (8) . Recent studies in the United Kingdom indicated that only 30 to 50% of patients with M. pneumoniae "infection" had symptoms, and of these only 10% had pneumonia (12) . The occurrence and distribution in nature of antigens shared by the membrane of M. pneumoniae should be emphasized. Such diverse organisms as M. pneumoniae (18) , M. neurolyticum (14) , and M. mycoides (4) share antigens which cross-react with antibodies specific for the lipid moiety of the M. pneumoniae membrane. Therefore, although antilipid antibodies can be removed by adsorption with M. pneumoniae membrane glycolipids, all individuals with pre-existing antilipid antibody need not have had prior M. pneumoniae infection. The extent of immunological cross-reaction between antibody to M. pneumoniae lipids and other similar antigens in the environment and the extent of human responses to homologous antigens are subjects of current interest and importance in the understanding of the epidemiology of M. pneumoniae infections.
